Retatrutide dosage in 2026: how the trial titration works

Retatrutide dosage in clinical trials follows a simple ladder: start at 2mg once a week, then step up every 4 weeks to 4mg, 8mg, and up to 12mg. Climbing slowly gives the body time to adjust and eases side effects. One key point up front: retatrutide is still investigational. It isn't sold as a legitimate compounded product yet. pru offers compounded semaglutide and tirzepatide instead, prescribed by a physician. Researching your options is a smart, proactive move, and the accessible path starts with a physician.

Retatrutide dosage at a glance

Retatrutide dosage in trials means a once-weekly injection that starts low and steps up over about 12 weeks. Cohorts in Eli Lilly's studies began at 2mg per week and increased by 2mg every 4 weeks, reaching maintenance doses of 4mg, 8mg, or 12mg. The half-life is roughly 6 days, which is why it's dosed once a week.

These numbers come from research studies, not a prescribing label. Retatrutide has no official prescribing dose because it's still investigational. If you want a GLP-1 you can actually get today, compounded semaglutide and compounded tirzepatide are the physician-prescribed options pru offers.

The retatrutide titration schedule used in trials

The retatrutide titration schedule steps up the dose every 4 weeks. This is the pattern Lilly used in its phase 2 and phase 3 studies. Starting at a low dose and raising it in small jumps helps the body get used to the medication.

Not everyone in the trials went all the way to 12mg. Some groups held at 4mg or 8mg. The idea is to find the lowest dose that works and stay there. For context on how this compares to available GLP-1s, see tirzepatide dosage and semaglutide dosage.

What each retatrutide mg dose means

Each retatrutide mg level is a maintenance dose, the amount a person stays on after titrating up. Higher doses were linked to more weight change in trials, but also to more side effects during the climb.

• 2mg: the starting dose in escalating trial arms, not a maintenance target
• 4mg: a lower maintenance dose; gentler on the stomach
• 8mg: a mid maintenance dose used across several trial groups
• 12mg: the highest maintenance dose studied in phase 2 and phase 3

Because retatrutide isn't approved, there's no official 'right' dose and no pharmacy that can legitimately dispense it. These figures describe what researchers tested, not a plan you can fill.

How retatrutide works in the body

Retatrutide is a triple agonist. It acts on three receptors at once: GLP-1, GIP, and glucagon. GLP-1 and GIP help curb appetite and steady blood sugar. The glucagon action is the newer piece; it may nudge the body to use more energy. That three-way design is why researchers watch it closely.

For a fuller walkthrough of the science and where it stands, read the retatrutide guide. To see how it stacks up against an available option, see retatrutide vs tirzepatide.

Why the dose starts low and climbs slowly

Retatrutide dosing starts low to reduce side effects. In the phase 2 trial, most side effects were stomach-related, mild to moderate, and happened during the dose-escalation weeks. Groups that started at 2mg and stepped up had fewer stomach problems than groups that jumped straight to a higher dose.

• Nausea, vomiting, and diarrhea were the most common effects
• They usually eased once a person settled at a steady dose
• A slower climb traded a bit of speed for a lot more comfort

This 'start low, go slow' rule holds for the GLP-1s you can actually get, too. If you're managing early nausea on a prescribed GLP-1, the nausea management guide walks through practical steps.

What each dose achieved in trials

Higher retatrutide doses were tied to larger average weight change in trials. These are research findings from studies Lilly ran, not promises for any individual. Nobody can predict your result from a trial average.

Phase 3 TRIUMPH-1 enrolled 2,339 adults and reported topline results in May 2026. The trials are large and the numbers are real, but they describe an investigational drug still under review.

Retatrutide is investigational, so no legitimate dose is for sale

Retatrutide is not FDA-approved and not available by prescription as of 2026. It isn't on the list of substances that compounding pharmacies can legally make. That means there's no legitimate way to buy a retatrutide dose right now, no matter what a website claims.

Lilly's likely FDA filing is late 2026 to early 2027, with a decision possibly in 2027. Until then, retatrutide stays a research topic. For more on why buying it now is a problem, see where to buy retatrutide and the retatrutide side effects overview.

The GLP-1 doses you can actually get

If you want a GLP-1 with a real dosing plan today, compounded semaglutide and tirzepatide are the physician-prescribed options. They share the same start-low, step-up approach as the retatrutide trials, and a licensed pharmacy fills them.

pru offers compounded semaglutide and compounded tirzepatide, both pharmacy-grade and compounded by a licensed pharmacy, not the branded products themselves. Browse the full weight loss and metabolism lineup to compare.

How pru handles retatrutide and GLP-1 dosing

pru does not currently offer retatrutide because it is still investigational and does not yet have a cleared, regulated compounding pathway. pru only offers peptides a licensed physician can prescribe and an FDA-registered 503A pharmacy can compound. Until retatrutide reaches that kind of overseen, legitimate pathway, the sound move is to wait for it rather than order a research-only vial with no prescriber or pharmacy behind it. We cover it here because people are searching for real answers, and a grey-market vial isn't one.

• You select the peptide you're interested in; a licensed physician confirms whether it's a fit for you
• Prescriptions are filled by FDA-regulated 503A compounding pharmacies, not shipped from a research supplier
• Peptides are priced at cost and itemized, with no member markup; a higher dose costs a little more in materials, never a hidden fee
• Membership runs about $50 a month; see pricing for the full breakdown

So the map is clear: retatrutide is a promising drug that isn't available yet, and compounded semaglutide or compounded tirzepatide are the compliant GLP-1s you can start with a physician now. Being proactive about your metabolic health is a responsible choice, and pru exists to make that choice accessible: licensed physicians, pharmacy-grade medicine, and at-cost pricing. Take the next step when you are ready.

Related reading on GLP-1 dosing

Keep going with these guides on dosing, side effects, and choosing a GLP-1:

• Retatrutide guide: what it is and where it stands
• Retatrutide vs tirzepatide
• Where to buy retatrutide (and the grey-market risk)
• Tirzepatide dosage
• Semaglutide dosage
• Best peptides for weight loss
• Shop weight loss and metabolism

Common questions